<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02775227</url>
  </required_header>
  <id_info>
    <org_study_id>HYKS-190116</org_study_id>
    <nct_id>NCT02775227</nct_id>
  </id_info>
  <brief_title>HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications</brief_title>
  <acronym>HYPAR</acronym>
  <official_title>HYPAR Trial - Hydrocortisone vs Pasireotide in Reducing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <brief_summary>
    <textblock>
      Pancreatic resections carry a high risk for complications, especially pancreatic fistula.
      Both hydrocortisone and pasireotide have been shown to be effective in reducing complications
      in earlier RCTs. The aim of this study is to compare the effectiveness and safety of these
      two drugs in preventing complications of pancreatic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Comprehensive Complication Index</measure>
    <time_frame>30 days postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications (Clavien-Dindo classification)</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pancreatic fistula (ISGPS-classification)</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative delayed gastric emptying (ISGPS-classification)</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-pancreatectomy hemorrhage (ISGPS-classification)</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay, days</measure>
    <time_frame>During hospital stay, on average 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>30 days postoperatively</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients receiving adjuvant therapy</measure>
    <time_frame>6 months postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Pancreatic Fistula</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pasireotide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide</intervention_name>
    <arm_group_label>Pasireotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for pancreatic surgery (pancreaticoduodenectomy, distal
             pancreatectomy, enucleation, or other type of pancreatic resection)

        Exclusion Criteria:

          -  Preoperative exclusion criteria:

          -  Atrophic pancreas and/or dilated pancreatic duct at the site of planned pancreatic
             transsection (applies only to patients undergoing pancreaticoduodenectomy)

          -  Total pancreatectomy planned

          -  Allergy or other contraindication for hydrocortisone or pasireotide

          -  Age &lt; 18 years

          -  No informed consent

          -  Intraoperative exclusion criteria:

          -  Pancreatic resection cancelled (e.g. disseminated cancer)

          -  Hard pancreas and/or dilated pancreatic duct discovered during operation (applies only
             to patients undergoing pancreaticoduodenectomy)

          -  Total pancreatectomy is performed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 14, 2016</study_first_submitted>
  <study_first_submitted_qc>May 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2016</study_first_posted>
  <last_update_submitted>April 28, 2019</last_update_submitted>
  <last_update_submitted_qc>April 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville Sallinen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

